Supply Chain

In this part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ Senior Director of DSCSA/Serialization Compliance Services, discusses the state of affairs surrounding the Drug Supply Chain Security Act, along with opportunities for improvement.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Michael Rowe, Two Labs’ Senior Director of DSCSA/Serialization Compliance Services, offers a brief overview of the Drug Supply Chain Security Act.

Per the deal, DKSH inherits the specialty pharma company’s Asia-Pacific medication portfolio.

In the final portion of his Pharma Commerce video interview, Dan Gagnon, UPS Healthcare’s VP of Global Strategy & Acquisition Integration, discusses the value in needle-to-needle and precision logistics, including its impact over the course of the next five years.

In this part of his Pharma Commerce video interview, Dan Gagnon, UPS Healthcare’s VP of Global Strategy & Acquisition Integration, dives into the challenges of safeguarding these products, while also sharing his keys to sustaining stability in the ‘recession resistant’ healthcare industry.

The climb is headlined by a 14.1% increase in total demand, according to the IATA.

Peter Ax provides insight as to industry’s lack of supply, along with how to mitigate these issues.

The agreement revolves around providing and maintaining supply chain transparency.

How teamwork among safety-net healthcare providers and pharma can make the difference.

The clinical supply facility undergoes a $25 million expansion, welcoming 32,000 more square feet of temperature-controlled storage.

In an interview with Pharma Commerce editor Nicholas Saraceno, Peter Ax, UpScriptHealth’s founder and CEO, discusses how patients are affected by these supply chain bottlenecks, along with ways to mitigate these complications.

In an interview with Pharma Commerce editor Nicholas Saraceno, Peter Ax, UpScriptHealth's founder and CEO, offers his thoughts surrounding the lack of supply.

Double-digit, year-on-year growth is now on a six-month streak.

The deal offers member pharmacies two pricing options, which will take effect Aug. 1.

The deal also adds a spread of supply chain efficiency, sustainability, and patient safety outcomes to the mix.

The contract manufacturer financially committed over $107 million into the facility, which can reportedly handle large-scale manufacturing of active ingredients based on messenger ribonucleic acid.

Webinar dives into the trends, technology, and market necessities that can help tackle these obstacles.

LogiPharma Europe captured many timely topics, including the importance of next-level approaches in aligning temperature-controlled transit and visibility.

Causal mediation analysis sought to determine how public hesitancy plays a role in the government procurement of certain vaccines.

New innovations that are contributing to industry environmental efforts.

An analysis of the general medicine portion of the pharmacy market amid ensuing challenges.

The new plant in Italy is expected to tackle the rise in biopharmaceutical material demand, specifically for GLP-1s.

These advancements continue to act as a key driver in helping to boost the security, efficiency, and innovation of global industries, include pharma.

According to the IATA, the streak continues—April represents the fifth consecutive month of positive development.

The Texas facility helps meet the cross-border logistics demand created by nearshoring.

The SSC strives to simply and add efficiencies to the scheduling technology used by the logistics sector.

Chip Davis recaps the organization’s Distribution Management Conference and addresses distributors’ preparedness for DSCSA implementation.

The company has financially committed $13.1 million into the project.

In an interview with Pharma Commerce Editor Nicholas Saraceno at LogiPharma Europe, Nick Porter, President, World Courier discusses mitigating supply chain risks, the future of artificial intelligence in pharma logistics, and more.

Parties sign co-exclusive licensing agreement, which includes a minority equity investment in Novavax, who will be receiving payments totaling as high as $1.2 billion when combining upfront payment and milestones.